Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NVfSWFB5TnWwY4Tpc44hSXO|YYm= NXyyOZprOC5zLUOwJO69VQ>? MVy0PEBp NXnJXlFVcW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? NWXvWVFFOjZ3MUOxO|I>
H460 MU\GeY5kfGmxbjDBd5NigQ>? MkC4NE4yNTNyIN88US=> NIDiVFk1QCCq MVPpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NHLn[HMzPjVzM{G3Ni=>
HKESC-2 NYLVV2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm1O3QzOMLizszN MYC0POKhcMLi MUfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> M3X2UlI3PDd2Nkmz
CaES-17 M2K0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHWVHdzOjEEoN88US=> MWW0POKhcMLi NYfUU|F1e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi M2DERVI3PDd2Nkmz
HKESC-2 MlPNRZBweHSxc3nzJGF{e2G7 NFzWO28zOMLizszN MUO0POKhcMLi M3Hze5Jm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NUCy[WdQOjZ2N{S2PVM>
CaES-17 MlzVRZBweHSxc3nzJGF{e2G7 MUCyNOKh|ryP NILabFM1QMLiaNMg NWjGT3BMemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? MX6yOlQ4PDZ7Mx?=
A549 M1rhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe1MVE3OCEQvF2= M2TnUlQ5yqCqwrC= Mn\vSG1UVw>? MmfETWM2OD1zNkOuOEDPxE1? NYLSVlc5OjZ2NkS2OFM>
HCC827 NVjvfml3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfnUWxIPS1zNkCg{txO NIfEWHU1QMLiaNMg MYfEUXNQ M125emlEPTB;NkmuNkDPxE1? NGLacGwzPjR4NE[0Ny=>
A549 NICxTlFCeG:ydH;zbZMhSXO|YYm= Mm[wPFAhyrWP MnvQOFjDqGkEoB?= M4rxb2ROW09? MnLybY5lfWOnczDhdI9xfG:|aYO= M160N|I3PDZ2NkSz
HCC827 M2\GT2Fxd3C2b4Ppd{BCe3OjeR?= Ml\LPFAhyrWP M3fDelQ5yqCqwrC= NEXqepZFVVOR NWnmWJVOcW6mdXPld{BieG:ydH;zbZM> M4\BcFI3PDZ2NkSz
SGC-7901/DDP M4S1NGZ2dmO2aX;uJGF{e2G7 NEnkUZQyOMLiwsXN MlLMNlQhcA>? Ml;obY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> NYPv[5Z{OjZ2MEe2OVM>
SGC-7901  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XFeFI1yqCqwrC= MkLrTWM2OD1zMUWuNFgh|ryP MYKyOlQxPzZ3Mx?=
SGC-7901/DDP Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmyOOKhcMLi NFH1N5RKSzVyPUO1MlQ2KM7:TR?= NHXnVVAzPjRyN{[1Ny=>
SGC-7901/DDP M4W4NGFxd3C2b4Ppd{BCe3OjeR?= M2jiNVExyqEEtV2= M2mwOlI1KGh? MoG0bY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> MW[yOlQxPzZ3Mx?=
SGC-7901/DDP NFjzU4NHfW6ldHnvckBCe3OjeR?= NXvSTGFVOTEEoNM1US=> MXmyOEBp NHK5[FdqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?= NGDJTIczPjRyN{[1Ny=>
SGC-7901/DDP M{XDU2Z2dmO2aX;uJGF{e2G7 MmPMNVDDqML3TR?= M{X5WVI1KGh? MnTRZ4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu NH3EdJUzPjRyN{[1Ny=>
H357 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ixclcvPS9zMDFOwG0> MUS0PEBp M2jERmROW09? MkTHbY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=> MWqyOlAxQTh5NB?=
TAF M2f3W2Z2dmO2aX;uJGF{e2G7 Mn24NVDDqML3TR?= MoT6O{Bl NXHWZm9u[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= NULuW3JXOjV7OEexNlc>
TAF MlfESpVv[3Srb36gRZN{[Xl? M{\pb|ExyqEEtV2= MnLvN|AuOTJyIH3pci=> NUP2NJJyeG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o NV\4ZWc3OjV7OEexNlc>
TAF NYTHSodZTnWwY4Tpc44hSXO|YYm= NVzWbIpbOTEEoNM1US=> NFTVUIc1QCCq MWnpcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NV\KU5lFOjV7OEexNlc>
PANC-1 M1:3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln4NlAwPjBxMUCwJO69VQ>? MYSyOE81QC95MjDo MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHnjSFAzPTl5M{C2Ni=>
PANC-1 NILOPXBHfW6ldHnvckBCe3OjeR?= NU\DXpZ4OjBxNkCvNVAxKM7:TR?= NH3acIczPCCq MV3heJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> Mk\iNlU6PzNyNkK=
HeLa  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;2TohrOjEEoN88UeKh MUiyOOKhcA>? Mn7h[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? MlPrNlU4PzB2MkO=
SACC-83 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HTRVIxyqEQvF5CpC=> NIPyOVkzPMLiaB?= MYTlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? M{nablI2PzdyNEKz
HeLa  NYf4S3M{SXCxcITvd4l{KEG|c3H5 M{PVTFIxyqEQvF5CpC=> M3PvOFI1yqCq NFTkRo9mdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ MWGyOVc4ODR{Mx?=
SACC-83 Mo\BRZBweHSxc3nzJGF{e2G7 Mo\nNlDDqM7:TdMg MX:yOOKhcA>? NVfXSXlY\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? MoHkNlU4PzB2MkO=
HeLa  Mo\DSpVv[3Srb36gRZN{[Xl? Ml\iNlAwPDBxOECg{txO MoTpNlTDqGh? M4HyNpVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV MU[yOVc4ODR{Mx?=
SACC-83 MXrGeY5kfGmxbjDBd5NigQ>? Mle2NlAwPDBxOECg{txO M{m2b|I1yqCq MWj1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> MnjuNlU4PzB2MkO=
HLCZ01 NUXCOXFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrYeFIx6oDVNkFCpOK2VQ>? NE\jc281QCCq MXfEUXNQ M3fRPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Ml;INlU4OjR6OUm=
HLCZ01 NGOxeFFHfW6ldHnvckBCe3OjeR?= MmDLOFDDqM7:TR?= MUCyOEBp NGG1fXVFVVOR M4LZ[4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NF;EWHEzPTd{NEi5PS=>
HLCZ01 NFvVepNCeG:ydH;zbZMhSXO|YYm= MkjUOFDDqM7:TR?= NYL2dHg5OjRiaB?= NFnmfXdFVVOR M1OzdoVvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? M1PKOFI2PzJ2OEm5
HLCZ01 NGnBNoNHfW6ldHnvckBCe3OjeR?= NH3ac3I1OMLizszN NF;sTlgzPCCq NHnO[m9FVVOR NHXaUFNqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE> M{\4dVI2PzJ2OEm5
MGC803 M1XPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMVYxKM7:TR?= M{H0WlczKGh? MnH1TWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= M4D1U|I2PzBzM{e4
SGC7901 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiwMVYxKM7:TR?= MX23NkBp NFH2eYJKSzVyPUSzMlU{6oDLwsJihKk2NjF{IN88US=> NEHVeo8zPTdyMUO3PC=>
MGC803 NHeyOGRHfW6ldHnvckBCe3OjeR?= Mn;jOFDDqM7:TR?= NFLZPFk5NzF4L{K0JIg> NHjVWol2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> M4e0elI2PzBzM{e4
SGC7901 MlPXSpVv[3Srb36gRZN{[Xl? NF\zTJA1OMLizszN NGDhSGk5NzF4L{K0JIg> MUf1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= NWHa[21DOjV5MEGzO|g>
MCF-7  NVvDSpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OzdVEwOTBizszN NULrdo1{PzJiaB?= NFPNUVFFVVOR M4PEUIVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MUOyOVY3PzVzMB?=
MDA-MB-231  NWCwbZR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHXXYoyNzFyIN88US=> NVf2eos{PzJiaB?= M4HOSGROW09? MorM[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? MUeyOVY3PzVzMB?=
MDA-MB-231 MULGeY5kfGmxbjDBd5NigQ>? M1XQbVAuPDBiwsXN MmfOOE0zPCCq M3rMTYlv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M1TLW|I2PTh5M{K5
MCF-7 M3zKdWZ2dmO2aX;uJGF{e2G7 NYm3bYZYOC12MDFCuW0> NEPPRmU1NTJ2IHi= MorN[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? MmXCNlU2QDd|Mkm=
MCF7-MX  Mn7OSpVv[3Srb36gRZN{[Xl? NF3ZUmYxNTRyINM1US=> MYm0MVI1KGh? MVXlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh M1Hqd|I2PTh5M{K5
MDA-MB-231 M4P1OGZ2dmO2aX;uJGF{e2G7 MWSwMVQxKML3TR?= NXnoRXROPC1{NDDo NUXUZWt5e3SrbYXsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCDQlPHNkB2eCC2bzC0MlI4KHSrbXXzJJRwKGOxboTyc4whdGW4ZXygZpkhOTJiaNMg M3S5W|I2PTh5M{K5
A2780 MVTGeY5kfGmxbjDBd5NigQ>? MYC1M|ExNzF3IN88US=> MVG0PEBp Mmj3[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXmyOVQzPDh7OB?=
SKOV3  NX;oUmRbTnWwY4Tpc44hSXO|YYm= M4iyVlUwOTBxMUWg{txO MmGyOFghcA>? NGnLZZBl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmHjNlU1OjR6OUi=
A2780 Mn7pSpVv[3Srb36gRZN{[Xl? NIDMc5Q2NzFyL{G1JO69VQ>? NHXGR2k1QCCq NXra[3o5\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= M3OxelI2PDJ2OEm4
SKOV3  MUPGeY5kfGmxbjDBd5NigQ>? M1ntflUwOTBxMUWg{txO MmmzOFghcA>? MUjlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv NXrTZVlCOjV2MkS4PVg>
A2780 MYrGeY5kfGmxbjDBd5NigQ>? M1HwNlUwOTBxMUWg{txO MXK0PEBp MXXk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? M4DOb|I2PDJ2OEm4
SKOV3  NILGPFVHfW6ldHnvckBCe3OjeR?= NX3wTotkPS9zMD:xOUDPxE1? NYrENnlSPDhiaB?= MorV[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw MnPyNlU1OjR6OUi=
A2780 MlPKSpVv[3Srb36gRZN{[Xl? MWm1M|ExNzF3IN88US=> MWSxJIg> NVrtR5AzcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWSyOVQzPDh7OB?=
SKOV3  Ml3ESpVv[3Srb36gRZN{[Xl? MnTOOU8yOC9zNTFOwG0> MVOxJIg> NVzwR4Z2cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlT6NlU1OjR6OUi=
HCT-15 M130fGZ2dmO2aX;uJGF{e2G7 MmK2NVAuPTBizszN NH\Nc3U3NTN4IHi= M2TvfYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MVWyOVIyQDB{OB?=
HT-29  MU\GeY5kfGmxbjDBd5NigQ>? NY\IXnpOOTBvNUCg{txO MWm2MVM3KGh? MnrYbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NInj[3czPTJzOECyPC=>
HSC3  M4nwfmNmdGxiVnnhZoltcXS7IFHzd4F6 NUXD[45OOOLCk{SwJO69VQ>? M{DRTlQ5KGh? MlrWTWM2OD1{NT61xtEyNjd6MDFOwG0> M1vzPFI2OTl6N{i5
HSC3  NVvrRW9HSXCxcITvd4l{KEG|c3H5 NVPuZ2ZTOjVizszN NYfaWFd7PDhiaB?= M3XMPYlv\HWlZYOgZZBweHSxc3nz NV7vcoFtOjVzOUi3PFk>
HSC3  M2TxemZ2dmO2aX;uJGF{e2G7 M4Tv[|I2KM7:TR?= NWfq[HpFPDhiaB?= MYnlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV MWOyOVE6QDd6OR?=
HSC3  NIjEOnhHfW6ldHnvckBCe3OjeR?= M1Lzd|I2KM7:TR?= NFLSVXA1QCCq NHfkOpNqdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ> NYnNU21nOjVzOUi3PFk>
HSC3  MoXGSpVv[3Srb36gRZN{[Xl? NYHRcFJxOjVizszN MnfLO|IhcA>? NEnLTppl\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> MX2yOVE6QDd6OR?=
201T  NV71VnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTsd5o4OiCq NGTnOYNFVVOR Ml7LTWM2OD12OD62JOK2VQ>? NVnudosyOjVyNUe5OFE>
273T NWjQWHd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnJO|IhcA>? Mni4SG1UVw>? M1TRT2lEPTB;OECuOUDDvU1? M{K5eFI2ODV5OUSx
Hep-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXnOY1GOzBxNUCvNVAxKM7:TR?= NFjp[2oyOi9{ND:zOk81QCCq NHz2UZVFVVOR NFHlTZZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3LIfVI1QTl6NU[0
Hep-2 M{PqT2Fxd3C2b4Ppd{BCe3OjeR?= MmD1OVAh|ryP M2nJdFAuPDhiaB?= NWL4eIZMTE2VTx?= NEfUOXFqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> M2WxWVI1QTl6NU[0
Hep-2 MlLESpVv[3Srb36gRZN{[Xl? MXq1NEDPxE1? NXzTXItLOC12ODDo M3PrbmROW09? MmTjdoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? NInoe5YzPDl7OEW2OC=>
Hep-2 Mn3mSpVv[3Srb36gRZN{[Xl? MWi1NEDPxE1? MX[wMVQ5KGh? NGLPNJdFVVOR MXzk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCqVFXSWC=> MVKyOFk6QDV4NB?=
SGC-7901 NIW4SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:5UpJGOTBxNUCvNVAxKM7:TR?= MnzaNlQwPDhxN{KgbC=> NYDGdVFkTE2VTx?= NIrOVVVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Ml7iNlQ6QTJ7NUi=
MKN-45 Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHrZo0yOC93MD:xNFAh|ryP MkfQNlQwPDhxN{KgbC=> NWXhZWFKTE2VTx?= NX\OOW9CcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NIfSfW4zPDl7Mkm1PC=>
SGC-7901 MXTGeY5kfGmxbjDBd5NigQ>? NET0XI0yOC93MD:xNFAh|ryP M1\0cFQ5KGh? NVXGcplXTE2VTx?= NWPM[2tF\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NUnnToo{OjR7OUK5OVg>
MKN-45 NYrVSmg1TnWwY4Tpc44hSXO|YYm= NXjHcHZWOTBxNUCvNVAxKM7:TR?= MUe0PEBp MmPySG1UVw>? Mn7w[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M13uSlI1QTl{OUW4
C666-1 NH\UNohEgXSxdH;4bYNqfHliQYPzZZk> M3Tz[lIxNThyIN88US=> M{nqcFI1KGh? MYLk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NYK4VnplOjR6NUS4N|g>
CNE-1 M{i5c2N6fG:2b4jpZ4l1gSCDc4PhfS=> NVHrdIdLOjBvOECg{txO MnvONlQhcA>? M1nyV4Rm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> M{\zeVI1QDV2OEO4
CNE-2 M1zVSGN6fG:2b4jpZ4l1gSCDc4PhfS=> MlOzNlAuQDBizszN MXuyOEBp M1\adIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NVf2SFRxOjR6NUS4N|g>
C666-1 NUfiPYdnS3m2b4TvfIlkcXS7IFHzd4F6 MWS2NEDPxE1? MmTxO{Bl M1zIRYVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy MmTWNlQ5PTR6M{i=
CNE-1 NV:xT|RmS3m2b4TvfIlkcXS7IFHzd4F6 MmHoOlAh|ryP MYW3JIQ> M33HXoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NVTCSoF3OjR6NUS4N|g>
SNU-1041 M{\yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TiR|AuPDBizszN M4HUWFQ5KGh? NYG0[m5{cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NE\NbHEzPDZ7MkewNy=>
SNU-1041 Ml3USpVv[3Srb36gRZN{[Xl? M{PyOVIxNzNyIN88US=> NH:0NXA1KGh? MXnpcoR2[2W|IHX4dJJme3Orb36gc4bDqEOKT2CsJGdTWDd6wrDhcoTDqFiEUEJCpIF1KHSqZTDSUmEhdGW4ZX|CpC=> MUSyOFY6OjdyMx?=
SNU-1041 MnT1SpVv[3Srb36gRZN{[Xl? M{fQR|AuPDBizszN NWLMZ5RbPCCq NWXVNWk2fXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= M4LkbFI1Pjl{N{Cz
SGC-7901 M333N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELrN5E2OC1zMkWg{txO NH:5RZYzPC92OD:3NkBp NX7Bb5BjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3\tTVI1Pjd4M{m0
SGC-7901 NX7sNW9[SXCxcITvd4l{KEG|c3H5 MonkNVAxKM7:TR?= MU[3NkBp M3vVdIlv\HWlZYOgZZBweHSxc3nz MmjuNlQ3PzZ|OUS=
SGC-7901 MUTGeY5kfGmxbjDBd5NigQ>? MWe3OU8yODBxMUK1JO69VQ>? M1rJ[FI1NzR6L{eyJIg> NUnYXlJncW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> NWDXN5Z3OjR4N{[zPVQ>
LMeC  MV3GeY5kfGmxbjDBd5NigQ>? MljTNlAwPTBizszN M{fJWlQ5KGh? M2nxXoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw NEXtPVYzPDZ3Nke0Oi=>
CMeC-1 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3zITFIxNzVyIN88US=> M{Lze|Q5KGh? MWnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXqyOFY2Pjd2Nh?=
LMeC MkfOR4VtdCCYaXHibYxqfHliQYPzZZk> MW[yNE82OCEQvF2= NILGU4E1QCCq MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXzR[mVuOjR4NU[3OFY>
CMeC-1 M{DkPGZ2dmO2aX;uJGF{e2G7 Mnf3NlAwPTBizszN M{\1[FQ5KGh? MYDpcoR2[2W|IFexMXMh[XK{ZYP0 M1jqOVI1PjV4N{S2
LMeC MljYSpVv[3Srb36gRZN{[Xl? M2f4WVIxNzVyIN88US=> NWjSe5NrPDhiaB?= MVzpcoR2[2W|IFexMXMh[XK{ZYP0 NH3rfIUzPDZ3Nke0Oi=>
CMeC-1 M{jZOGZ2dmO2aX;uJGF{e2G7 NEOwfXUzOC93MDFOwG0> M3W2O|Q5KGh? NXmxUmtz\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MojKNlQ3PTZ5NE[=
LMeC NGPs[IVHfW6ldHnvckBCe3OjeR?= NWPL[llFOjBxNUCg{txO NVez[nQyPDhiaB?= MWfk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYOyOFY2Pjd2Nh?=
CMeC-1 MVvGeY5kfGmxbjDBd5NigQ>? Ml;SNlAwPTBizszN NUDCc2poPDhiaB?= MlHabY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> M3njcFI1PjV4N{S2
LMeC MoDxSpVv[3Srb36gRZN{[Xl? MVeyNE82OCEQvF2= NIPu[481QCCq MnTBbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> NIDHVGQzPDZ3Nke0Oi=>
OVCAR-3 NFq0UVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYGwNnV3OTBiwsXN MYGxJIg> NFSxZpZmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh Mmn6NlQ2OjB{Mke=
OVCAR-3 MnjrRZBweHSxc3nzJGF{e2G7 NIO5eVgyOCEEtV2= M1\vS|EhcA>? MXnwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> MkX2NlQ2OjB{Mke=
OVCAR-3 M{fvT2Z2dmO2aX;uJGF{e2G7 NFjXNIIyOCEEtV2= NYXwZWlEOSCq NYj2eI5E\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> NIj2dHMzPDV{MEKyOy=>
OVCAR-3 MnniSpVv[3Srb36gRZN{[Xl? NHzsbYYyOCEEtV2= NHu3T2QyKGh? NXe3VnFU\G:5bj3y[Yd2dGG2ZYOgUmYu|rqEIHHjeIl3[XSrb36gbY5lfWOnZDDifUBx[WOuaYThfIVt M1LsXlI1PTJyMkK3
OVCAR-3 NYD5O2FKTnWwY4Tpc44hSXO|YYm= NV7qSXFNOTBiwsXN MmH1NUBp NFXrN5ZqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M3[5Z|I1PTJyMkK3
CF33 NYDvXW9LTnWwY4Tpc44hSXO|YYm= NXu5NmFYOTByIN88US=> MlTNNlQhcA>? NYHiXpgycW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36= MlfjNlQ2ODN5OEK=
CF33 NHPiWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSzTXZWOTBvMUCwJO69VQ>? MWGwMVQh\A>? M4fUN4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2T1OVI1PTB|N{iy
CF33 MULGeY5kfGmxbjDBd5NigQ>? NUXxS4NFOTBvMUCwJO69VQ>? Ml\FOE0zPCCq MYTk[YNz\WG|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q> NV;ZfYJJOjR3MEO3PFI>
LNCaP MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfKeZUzNzVxMUCg{txO NFrXNHU6PiCq MXnpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XSxco\hd5RifGmw MVuyOFI6Pjl5OB?=
LNCaP NHHjcGFCeG:ydH;zbZMhSXO|YYm= MWiyM|UwOTBizszN M1vmT|k3KGh? MknjbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= Ml:5NlQzQTZ7N{i=
PC-3  M2S1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\0O48xNTVyIN88US=> NFfkTJE1QOLCiXi= NYf0WphWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NYT6XVBoOjRzMke4PFI>
PC-3  M3rhRmNmdGxiVnnhZoltcXS7IFHzd4F6 MVOwMVExOCEQvF2= MUK3NkBp NVrUOXJE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NY[5W3hOOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID